Keywords: Novartis, COPD, Indacaterol, FDA advisory, Onbrez, Arcapta

Novartis COPD drug indacaterol gets mixed message from FDA advisory committee

Article | 09 March 2011

Print This

The US Food and Drug Administration should approve Swiss drug major Novartis’ (NOVN: VX) QAB149 (indacaterol) as the first ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in